Vapi, India– [21 July 2025] – A wholly owned subsidiary of the Abu Dhabi Investment Authority (“ADIA”) has entered into definitive agreements to invest USD 200 million for a ~3 per cent stake in Micro Life Sciences (“Meril”), one of India’s leading medical devices companies. This investment values Meril at an enterprise value of USD 6.6 billion. The transaction is subject to regulatory approval by the Competition Commission of India (CCI). Post this investment, Meril will be backed by two globally recognised investors, ADIA and Warburg Pincus.
Founded by the Bilakhia Group, Meril is a global innovator in medical technology (MedTech), with a strong focus on clinically advanced solutions across multiple specialties — including Cardiovascular, Structural Heart, Orthopaedics, Endo-surgery, In-vitro Diagnostics and Surgical Robotics.
Headquartered in Vapi, India, Meril operates state-of-the-art, vertically integrated, and globally certified manufacturing and R&D facilities, across a 100 acre sustainable MedTech campus. The company employs more than 13,000 people, has 35+ global subsidiaries, and serves healthcare systems in 150+ countries. Meril is committed to becoming the world’s leading MedTech company, powered 100 per cent by green energy, reinforcing its commitment to sustainable innovation.
With a robust in-house global R&D ecosystem and a portfolio of 200+ technology platforms, Meril continues to lead in global clinical research and education. Breakthrough innovations such as the Myval Transcatheter Heart Valve (THV) series, MyClip Transcatheter Edge-to-Edge Repair (TEER) system, and the MISSO Surgical Robotic System highlight Meril’s dedication to next-generation innovation. Through its 12+ global training academies, Meril empowers over 10,000 healthcare professionals annually.
Sanjeev Bhatt, Senior Vice President – Strategy, Meril said, “This investment by ADIA reinforces confidence in Meril’s long term vision and global ambitions. This investment will enable us to accelerate growth, attract world-class talent, and further strengthen our R&D and clinical research ehorts as we work towards improving the quality of human life through advanced healthcare solutions.”